Autopsy report · NCT00126867

Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment

“Insufficient accrual and no funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 13 years 11 months before it stopped.
• 29 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

AHS Cancer Control Alberta

Sponsor type

University, hospital or other

Conditions

Colon Cancer

Participants

29

Sites

1

Countries

Canada

Trials that died the same way

• Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
  “Insufficient funding” (85% match in meaning)
• Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
  “slow accrual; insufficient funding to continue to accrue” (82% match in meaning)
• Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
  “Insufficient funding/staff” (80% match in meaning)
• Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
  “Low Accrual, Funding” (78% match in meaning)
• Hatha Yoga in Breast Cancer Survivors
  “Insufficient staff and funding” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.